Review



cxcr1/2 inhibitors azd5069  (AstraZeneca ltd)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    AstraZeneca ltd cxcr1/2 inhibitors azd5069
    Cxcr1/2 Inhibitors Azd5069, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/azd5069/pm40524157-366-15-20
    Average 90 stars, based on 1 article reviews
    cxcr1/2 inhibitors azd5069 - by Bioz Stars, 2026-09
    90/100 stars

    Images

    Related Articles

    Mouse Assay:

    Article Title: Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling
    Article Snippet: .. Mice were then intraperitoneally injected with vehicle control (IgG2b control, clone LTF-2, 10mg/kg, Bio-X-Cell), AZD5069 (150mg/kg, AstraZeneca); anti-PD-L1 (clone 10F.9G2, 10mg/kg, Bio-X-Cell); AZD5069 (150 mg/kg) plus anti-PD-L1 (10mg/kg). (B and C) Tumor volume of the mice was monitored every 6 days by in vivo imaging as showed in the representative pictures. ..

    Injection:

    Article Title: Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling
    Article Snippet: .. Mice were then intraperitoneally injected with vehicle control (IgG2b control, clone LTF-2, 10mg/kg, Bio-X-Cell), AZD5069 (150mg/kg, AstraZeneca); anti-PD-L1 (clone 10F.9G2, 10mg/kg, Bio-X-Cell); AZD5069 (150 mg/kg) plus anti-PD-L1 (10mg/kg). (B and C) Tumor volume of the mice was monitored every 6 days by in vivo imaging as showed in the representative pictures. ..

    Control:

    Article Title: Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling
    Article Snippet: .. Mice were then intraperitoneally injected with vehicle control (IgG2b control, clone LTF-2, 10mg/kg, Bio-X-Cell), AZD5069 (150mg/kg, AstraZeneca); anti-PD-L1 (clone 10F.9G2, 10mg/kg, Bio-X-Cell); AZD5069 (150 mg/kg) plus anti-PD-L1 (10mg/kg). (B and C) Tumor volume of the mice was monitored every 6 days by in vivo imaging as showed in the representative pictures. ..

    In Vivo Imaging:

    Article Title: Overcoming immunotherapy resistance in hepatocellular carcinoma by targeting myeloid IL-8/CXCR2 signaling
    Article Snippet: .. Mice were then intraperitoneally injected with vehicle control (IgG2b control, clone LTF-2, 10mg/kg, Bio-X-Cell), AZD5069 (150mg/kg, AstraZeneca); anti-PD-L1 (clone 10F.9G2, 10mg/kg, Bio-X-Cell); AZD5069 (150 mg/kg) plus anti-PD-L1 (10mg/kg). (B and C) Tumor volume of the mice was monitored every 6 days by in vivo imaging as showed in the representative pictures. ..

    In Vitro:

    Article Title: Selective anti-CXCR2 receptor blockade by AZD5069 inhibits CXCL8-mediated pro-tumorigenic activity in human thyroid cancer cells in vitro.
    Article Snippet: .. The complete medium was supplemented with increasing concentrations of AZD5069 (100 pM–10 μM, kindly provided by AstraZeneca), the concentrations of AZD5069 were chosen based on previous in vitro studies [23, 25] and according to those reached in the sera of patients treated with this compound [26]. ..

    other:

    Article Title: Targeting IL-8 and Its Receptors in Prostate Cancer: Inflammation, Stress Response, and Treatment Resistance
    Article Snippet: AZD5069 (Astrazeneca) , ACE , CXCR2 , Small-molecule inhibitor , Phase 1 and 2: completed , AZD5069 in combination with enzalutamide. , NCT03177187 , Results described in .



    Similar Products

    azd5069  (MedChemExpress)
    95
    MedChemExpress azd5069
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Azd5069, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD-5069/pmc12496203-473-22-23
    Average 95 stars, based on 1 article reviews
    azd5069 - by Bioz Stars, 2026-09
    95/100 stars
    		  Buy from Supplier
    histology  (Selleck Chemicals)
    93
    Selleck Chemicals histology
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Histology, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-2-25-22
    Average 93 stars, based on 1 article reviews
    histology - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    lps inhi cxcr2  (Selleck Chemicals)
    93
    Selleck Chemicals lps inhi cxcr2
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Lps Inhi Cxcr2, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-134-44-63
    Average 93 stars, based on 1 article reviews
    lps inhi cxcr2 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cxcr2 inhibitor  (Selleck Chemicals)
    93
    Selleck Chemicals cxcr2 inhibitor
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Cxcr2 Inhibitor, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-134-59-63
    Average 93 stars, based on 1 article reviews
    cxcr2 inhibitor - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    pulpitis models  (Selleck Chemicals)
    93
    Selleck Chemicals pulpitis models
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Pulpitis Models, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-2-13-22
    Average 93 stars, based on 1 article reviews
    pulpitis models - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    lps injection  (Selleck Chemicals)
    93
    Selleck Chemicals lps injection
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Lps Injection, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-134-65-63
    Average 93 stars, based on 1 article reviews
    lps injection - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cxcr2 inhibitor azd5069  (Selleck Chemicals)
    93
    Selleck Chemicals cxcr2 inhibitor azd5069
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Cxcr2 Inhibitor Azd5069, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm41589026-2-18-22
    Average 93 stars, based on 1 article reviews
    cxcr2 inhibitor azd5069 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier
    cxcr1/2 inhibitors azd5069  (AstraZeneca ltd)
    90
    AstraZeneca ltd cxcr1/2 inhibitors azd5069
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Cxcr1/2 Inhibitors Azd5069, supplied by AstraZeneca ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/azd5069/pm40524157-366-15-20
    Average 90 stars, based on 1 article reviews
    cxcr1/2 inhibitors azd5069 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    azd5069  (Selleck Chemicals)
    93
    Selleck Chemicals azd5069
    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of <t>AZD5069,</t> a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.
    Azd5069, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/azd5069/AZD5069/pm40412356-156-4-18
    Average 93 stars, based on 1 article reviews
    azd5069 - by Bioz Stars, 2026-09
    93/100 stars
    		  Buy from Supplier

    Image Search Results


    Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of AZD5069, a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.

    Journal: iScience

    Article Title: Microenvironmental signals combine to induce non-additive molecular and phenotypic responses in mammary epithelial cells

    doi: 10.1016/j.isci.2025.113407

    Figure Lengend Snippet: Synergistic transcriptional upregulation of CXCR2 chemotactic signaling molecules via CREB activation promotes increased cell motility (A) Cell motility assays following treatment with single and combination ligand panels in the presence or absence of AZD5069, a CXCR2 inhibitor. CXCR2 inhibition significantly decreased cell motility in the EGF+OSM, EGF, and OSM conditions. Data shown as median change in motility and error bars representing the standard deviation from three biological replicates. ANOVA followed by post-hoc Tukey’s honest significant difference test was used to assess significance, with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (B) Reverse phase protein array (RPPA) analysis 1 h after treatment with EGF, OSM, and EGF+OSM. Median phosphorylation ratio is shown, with error bars representing standard deviation. Statistically significant changes in protein expression ( p -value <0.05) were assessed using Dunnett’s test ( n = 3). (C) Effects of CREB knockdown on the cell motility of cells treated with EGF, OSM, or EGF+OSM. Mean squared displacement (MSD) is shown in the top panel and change in motility is shown in the bottom. Median change in motility is shown, with error bars representing standard deviation. Tukey’s honest significant difference test was used to assess significance with p -value <0.05 considered significant ( n = 3). ∗ p < 0.05. (D) ELISA analysis of chemokine expression in CREB knockdown cells following EGF+OSM treatment. Bar plots depict mean protein expression in conditioned media, with error bars representing the 95% confidence interval. Student’s t test was used to assess significance ( p -value <0.05) ( n = 3). ∗ p < 0.05, ∗∗ p < 0.01. (E) Putative mechanism of the synergistic activation of CREB in response to combined EGF and OSM stimulation drives the upregulation of CXCL3, CXCL5, and PPBP, leading to increased cell motility via CXCR2 activation.

    Article Snippet: After cell attachment and subsequent culture in assay media, 3 nMol Trametinib (Selleckchem, #S2673), 1 μMol Alpelisib (Selleckchem, #S2814), or 5 nM AZD5069 (MedChemExpress, #19855) or DMSO was added along with the ligand treatments.

    Techniques: Activation Assay, Inhibition, Standard Deviation, Protein Array, Phospho-proteomics, Expressing, Knockdown, Enzyme-linked Immunosorbent Assay